During the past decade, QdotPharma conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "QdotPharma" are "Pulmonary Disease, Chronic Obstructive" (2 trials). Many other conditions were trialed in "QdotPharma" in a lesser frequency.

Most popular intervention types in "QdotPharma" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d." (1 trials), "Salmeterol plus Fluticasone" (1 trials), "Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)" (1 trials) and "Tiotropium" (1 trials). Other intervention names were less common.

The vast majority of trials in "QdotPharma" are 2 trials for "All" genders.

Currently, there are NaN active trials in "QdotPharma". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in QdotPharma, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in QdotPharma, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".